High rates of 30-day mortality in patients with cirrhosis and COVID-19.

ABSTRACT:

Background & aims

Coronavirus disease 2019 (COVID-19) poses a major health threat to healthy individuals and those with comorbidities, but its impact on patients with cirrhosis is currently unknown. Herein, we aimed to evaluate the impact of COVID-19 on the clinical outcome of patients with cirrhosis.

Methods

In this multicentre retrospective study, patients with cirrhosis and a confirmed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection were enrolled between 1^st and 31^th March 2020. Clinical and biochemical data at diagnosis of COVID-19 and at the last outpatient visit were obtained through review of medical records.

Results

Fifty patients with cirrhosis and confirmed SARS-CoV-2 infection were enrolled (age 67 years, 70% men

SUBMITTER: Iavarone M 

PROVIDER: S-EPMC7280108 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature